




FIG. 1




FIG. 2A-D




FIG. 2E-G




FIG. 3




FIG. 4




FIG. 5




FIG. 6A-B




FIG. 6C-G




FIG. 7A-B




FIG. 7C-D




FIG. 8




FIG. 9




FIG. 10




FIG. 11A




FIG. 11B




FIG. 12




FIG. 13





FIG. 14A

Cancer type	Cell line	SALL4 dependency*	72h EC ₅₀ (µM)				
			QE-18-WG07	RE	CC-61	CC-88	VB
HCC	SNU-398	dependent	0.31	0.45	12.0	21.7	2.67
HCC	SNU-387	independent	3.27	0.75	>90	74.8	8.02
HCC	SNU-449	independent	>30	0.96	>90	52.5	58.2
NSCLC	H661	dependent	0.42	0.38	66.7	66.9	31.0
NSCLC	H1299	independent	30.0	2.67	>90	>90	>90


*Cancer cell dependency on SALL4 for survival validated by SALL4B-specific knockdown via shRNA

FIG. 14B

A



QE-18-WG07



Thalidomide: Y = O, R = H
Pomalidomide: Y = O, R = NH₂

B

QE-18-WG07 vs. Pomalidomide 9h
SALL4B_Luc Level




FIG. 15A-B




FIG 15C






FIG. 15D-E






FIG. 16D-F




FIG. 17




FIG. 18





FIG. 19






FIG. 21




FIG. 22A-C




FIG. 22D-F




FIG. 23